Organisation: Alkermes’

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Dublin drug firm Alkermes gets FDA go-ahead for schizophrenia treatment

Dublin-headquartered pharmaceutical firm, Alkermes has gained US regulatory approval to start marketing its schizophrenia treatment, Aristada.

Wed, 07 Oct, 2015

Drugmaker revenues beat analyst estimates

Dublin-based US drugmaker Alkermes has reported a 14% year-on-year increase in third-quarter net revenue to $160m (€125m), beating analyst forecasts.

Thu, 30 Oct, 2014

Alkermes raises profit forecast

Irish-American pharmaceutical company Alkermes has increased its full-year profit forecast for the second time in three months.

Fri, 01 Feb, 2013

Alkermes sees revenues rise by 185%

Alkermes — the US biopharmaceutical group — has witnessed the first benefits of its takeover of Elan’s Athlone-based drug delivery arm, with third-quarter revenues rising by more than 185%.

Fri, 03 Feb, 2012

Elan sells Athlone drug unit in $960m cash and equity deal

ELAN has agreed to sell its Athlone, Co Westmeath- based drug delivery unit EDT (Elan Drug Technologies) to US firm Alkermes for nearly $1 billion in a cash and equity deal.

Tue, 10 May, 2011